A 94-Day Marijuana Study Tracked Heart Rate and Reported High Across Smoking Periods

A 1977 supervised study reported declining mean heart-rate and subjective-high responses during marijuana smoking periods. Both light and heavy smokers showed evidence of tolerance, although their response levels differed.

The study included intervening drug-free periods

Thirty participants were followed over ninety-four days with smoking and drug-free intervals. Heart rate and subjective high were tracked over the smoking period. The design therefore provided repeated observations rather than a single comparison between experienced and inexperienced users.

Group differences and within-period adaptation were separate

Light smokers had greater heart-rate and subjective responses than heavy smokers. Both groups nevertheless showed tolerance. A lower response in an experienced group and a decline over repeated exposure are related findings, but they do not answer exactly the same causal question.

The endpoints did not cover all impairment domains

The abstract also noted accumulation and minor withdrawal effects without detailed quantification. It does not supply a complete pharmacokinetic model or a standardized cognitive-performance result. A reduced reported high cannot be treated as a validated measure of preserved functioning.

The study contributes a longitudinal historical comparison of two common tolerance endpoints. It does not establish that frequent users have no cardiovascular response or that either group was safe to drive. Sample, smoking conditions and the limited measures should accompany any statement derived from the report.

Related: interpreting cannabis tolerance claims.

Research cited

Nowlan R; Cohen S. Tolerance to marijuana: heart rate and subjective "high". Clinical pharmacology and therapeutics (1977). doi:10.1002/cpt1977225part1550. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Psychiatric CBD Review’s Recommendation Grades Included Both CBD and THC-Containing Nabiximols

A review published in 2020 graded psychiatric evidence from studies of CBD and CBD-containing nabiximols. Its recommendation labels should not be quoted as though every underlying intervention was purified CBD or every study was randomized. The included designs ranged widely The review identified 23 relevant studies spanning case reports, case…

Spread the love

Read Article: A Psychiatric CBD Review’s Recommendation Grades Included Both CBD and THC-Containing Nabiximols

CBD Eye Research: Molecular Targets and Clinical Ocular Treatment Are Different Evidence Levels

A 2021 ocular CBD review brought together in-vitro and in-vivo research, proposed molecular targets and possible therapeutic applications. This evidence maps a development pathway; it does not establish that CBD products are effective eye treatments. The experimental system belongs in the conclusion A cellular result can identify a target or…

Spread the love

Read Article: CBD Eye Research: Molecular Targets and Clinical Ocular Treatment Are Different Evidence Levels

CBD Addiction Research Measures Reinforcement, Motivation and Withdrawal as Different Outcomes

A 2021 review evaluated CBD research on reinforcing, motivational and withdrawal-related drug effects. These outcomes can inform substance-use-disorder research, but an improvement in one cannot establish successful treatment across all of them. The source combined preclinical and clinical reports The review covered alcohol, opioids, cannabinoids, nicotine and psychostimulants. An animal…

Spread the love

Read Article: CBD Addiction Research Measures Reinforcement, Motivation and Withdrawal as Different Outcomes

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us